UK’s NICE Xalkori Recommendation Signals Issues For Securing Market Access For Rarer Cancer Drugs
Executive Summary
Two more drugs are set to enter England’s Cancer Drugs Fund: Tesaro’s Zejula and Pfizer’s Xalkori. Recommendations on the latter highlight difficulties for rarer cancer treatments.